Introduction: Neuroblastoma (NB) is the third most common solid tumor in children, originating from neural crest cells and associated with the peripheral sympathetic nervous system. This pediatric neoplasm is highly aggressive and heterogeneous, with clinical outcomes ranging from spontaneous regression to fatal outcome. Despite therapeutic advances, conventional multimodal treatments remain insufficient, especially in high-risk cases characterized by resistance and poor prognosis. The immunosuppressive tumor microenvironment in NB contributes significantly to treatment resistance, highlighting the need for more effective therapeutic alternatives. In this context, natural compounds have emerged as promising antitumor agents. Baicalein, a flavonoid extracted from the dried roots of Scutellaria baicalensis Georgi, has remarkable pharmacological properties. Previous studies have shown that baicalein exerts antitumor effects through the induction of autophagy, inhibition of angiogenesis, and suppression of cell proliferation. Although its efficacy has been reported in various cancers, the mechanisms underlying its action and therapeutic potential in NB are not yet fully. Objective: The aim of this study was to investigate the effects of baicalein on two human NB cell lines (IMR-32 and SHSY-5Y) and on the normal lung fibroblast cell line (MRC-5). Methods: Cell viability was assessed using the resazurin assay after 24, 48, and 72 hours of baicalein exposure. The Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit was used to quantify seven inflammatory cytokines (IL-2, IL- 4, IL-6, IL-10, IL-17, IFN-?, and TNF) in all three cell lines. Results: Our results show that baicalein significantly inhibited cell proliferation of the IMR-32 cell line in a dose- and time-dependent manner. The SHSY-5Y cell line exhibited greater resistance to baicalein, with significantly higher IC50 values compared to the other cell lines. In addition, baicalein modulated the expression of several cytokines, with a marked, concentration-dependent suppression of IL-6 observed across all cell lines. For other cytokines, baicalein showed selective modulation, with IMR-32 cells showing increased sensitivity in the regulation of inflammatory mediators. Conclusions: These results suggest that baicalein has the potential to be used as an adjuvant therapeutic for NB. The consistent reduction of IL-6 levels in all cell lines suggests a possible inhibition of the JAK/STAT pathway, which is crucial for IL-6 production and is often hyperactivated in tumors. Thus, baicalein may contribute to the suppression of tumor growth and modulation of the inflammatory microenvironment in NB, and may represent a promising alternative for future therapeutic strategies.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
